Notice 26 Jun 2025 regulation, healthcare compliance, dea, controlled substances, drug enforcement administration, nursing

⚖️DEA Suspension of Registrant

The Drug Enforcement Administration's recent order revokes Scott Hansen's registration due to allegations of improper prescribing while his nursing license was suspended. The case highlights critical compliance issues regarding the authority of healthcare practitioners to prescribe controlled substances, emphasizing the importance of adherence to both federal and state regulations.

Learn More
Notice 26 Jun 2025 regulatory compliance, healthcare, california, dea, drug enforcement, medical licensing

🚫DEA Revokes Registration of Dr. Bohdan Olesnicky

The Drug Enforcement Administration has revoked the DEA registration of Dr. Bohdan Olesnicky due to his lack of authority to practice medicine in California, following his voluntary surrender of his medical license. This action highlights the necessity for healthcare professionals to maintain state licensure to manage controlled substances legally under federal law.

Learn More
Notice 23 Jun 2025 regulatory compliance, california, dea, drug enforcement, medical licensing

⚖️Revocation of DEA Registration for William Thompson IV, M.D.

The Drug Enforcement Administration (DEA) has issued a revocation order for the DEA registration of William Thompson IV, M.D., citing lack of authority to handle controlled substances due to the revocation of his California medical license. The order underscores the importance of maintaining state licensing for medical practitioners engaged in dispensing controlled substances.

Learn More
Notice 18 Jun 2025 compliance, regulation, pharmaceutical industry, clinical trials, dea, controlled substances, drug enforcement

💊DEA Notice on AndersonBrecon's Controlled Substance Import Application

AndersonBrecon, Inc. DBA PCI Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 18 Jun 2025 compliance, regulatory requirements, manufacturing, dea, controlled substances, drug enforcement

💊DEA Notice

Veranova, L.P., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 18 Jun 2025 regulatory compliance, manufacturing, pharmaceutical, dea, controlled substances, drug enforcement

💊American Radiolabeled Chem's Controlled Substances Manufacturing Application

American Radiolabeled Chem has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 10 Jun 2025 regulatory compliance, healthcare, new jersey, dea, controlled substances, medical licenses

⚖️DEA Revokes Registration for Serge Menkin, M.D. Due to Non-Compliance

The Drug Enforcement Administration (DEA) has issued an Order to Show Cause for the revocation of Dr. Serge Menkin's registration, citing his lack of authority to handle controlled substances due to an inactive license. The order underscores the necessity for practitioners to maintain compliance with state licensing laws to engage in dispensing controlled substances.

Learn More
Proposed Rule 10 Jun 2025 regulatory compliance, administrative practice and procedure, reporting and recordkeeping requirements, pharmaceutical industry, dea, controlled substances, drug traffic control, drug enforcement, chemical research, 3-meo-pcp

⚖️Proposed Schedule I Classification for 3-Methoxyphencyclidine

The Drug Enforcement Administration proposes placing 3- methoxyphencyclidine, including its salts, isomers, and salts of isomers, an arylcyclohexylamine hallucinogen, in schedule I of the Controlled Substances Act. This action is proposed to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess), or propose to handle 3-methoxyphencyclidine.

Learn More
Notice 10 Jun 2025 healthcare, regulation, california, dea, drug enforcement

❌DEA Revokes Registration of Harry Kram, M.D.

The Drug Enforcement Administration issues an Order to Show Cause against Dr. Harry Kram, citing the revocation of his ability to handle controlled substances in California due to expired medical credentials. The order also outlines the implications for his DEA registration and the failure to respond to hearing requests.

Learn More
Notice 9 Jun 2025 regulatory compliance, healthcare, california, dea, drug enforcement, medical practice

⚖️High-Impact DEA Registration Revocation Notice for Medical Practitioners

The Department of Justice has ordered the revocation of Ron Dunchok, M.D.'s DEA registration due to legal noncompliance with state licensing requirements. This decision is significant for businesses in the pharmaceutical and healthcare sectors, emphasizing the need for adherence to state laws for the dispensing of controlled substances.

Learn More